Vildagliptin (Sustained Release),Dapagliflozin & Metformin Hydrochloride (SR) Tablets – Vildos DM 100/10/500 SR Tablets

Vildos DM 100/10/500 SR Tablets
Composition:- Vildagliptin (Sustained Release) 100 mg + Dapagliflozin 10 mg + Metformin (Sustained Release) 500mg

Vildos DM 100/10/500 SR Tablets – Vildagliptin (Sustained Release), Dapagliflozin & Metformin Hydrochloride (SR) Tablets is a triple combination anti-diabetic formulation designed for comprehensive glycemic control in Type 2 Diabetes Mellitus. Vildagliptin helps improve insulin secretion and reduce glucagon levels, Dapagliflozin promotes urinary glucose excretion, while Metformin SR helps decrease hepatic glucose production and improves insulin sensitivity. The sustained-release formulation supports prolonged action, better glycemic stability, and improved patient compliance.

Marketed by: Wonne International Pvt. Ltd.

Key Points of Vildagliptin (Sustained Release),Dapagliflozin & Metformin Hydrochloride (SR) Tablets – Vildos DM 100/10/500 SR Tablets

• Triple Action Glycemic Control: Combines three complementary anti-diabetic agents for effective blood sugar management.
• Supports Insulin Regulation: Vildagliptin enhances glucose-dependent insulin release and helps control glucagon secretion.
• Promotes Glucose Elimination: Dapagliflozin helps remove excess glucose through urine by SGLT2 inhibition.
• Improved Insulin Sensitivity: Metformin SR helps reduce hepatic glucose output and supports better insulin utilization.
• Sustained-Release Advantage: SR formulation provides prolonged therapeutic action with enhanced patient convenience.

Can be Prescribed by:

• Diabetology
• Endocrinology
• General Medicine
• Healthcare practitioner

Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.